While the gene therapy field has suffered a series of setbacks of late, with a number of trials being paused due to safety concerns and investors being spooked, the fundamentals of the sector remain in good shape.
Purespring Positive About Prospects Despite Burst Biotech Bubble
UK Gene Therapy Moving Quickly Towards Clinic
Some investors are shying away from early-stage gene therapy companies, but Richard Francis, CEO of kidney disease specialist Purespring, told Scrip that the pharmaceutical industry's appetite for the field has not waned and the best-equipped companies will flourish.

More from Gene Therapies
Adstiladrin sales hit €70m in first full year on the market
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
More from Advanced Therapies
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.